JP2019512251A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019512251A5 JP2019512251A5 JP2018549452A JP2018549452A JP2019512251A5 JP 2019512251 A5 JP2019512251 A5 JP 2019512251A5 JP 2018549452 A JP2018549452 A JP 2018549452A JP 2018549452 A JP2018549452 A JP 2018549452A JP 2019512251 A5 JP2019512251 A5 JP 2019512251A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- host cell
- amino acid
- nucleic acid
- acid molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023045262A JP7746323B2 (ja) | 2016-03-23 | 2023-03-22 | Ｐｄ－１及び４－１ｂｂの融合タンパク質 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LULU93006 | 2016-03-23 | ||
| LU93006 | 2016-03-23 | ||
| PCT/EP2017/056931 WO2017162797A1 (en) | 2016-03-23 | 2017-03-23 | Fusion proteins of pd-1 and 4-1bb |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023045262A Division JP7746323B2 (ja) | 2016-03-23 | 2023-03-22 | Ｐｄ－１及び４－１ｂｂの融合タンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019512251A JP2019512251A (ja) | 2019-05-16 |
| JP2019512251A5 true JP2019512251A5 (https=) | 2019-09-19 |
| JP7250519B2 JP7250519B2 (ja) | 2023-04-03 |
Family
ID=55702054
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018549452A Active JP7250519B2 (ja) | 2016-03-23 | 2017-03-23 | Ｐｄ－１及び４－１ｂｂの融合タンパク質 |
| JP2023045262A Active JP7746323B2 (ja) | 2016-03-23 | 2023-03-22 | Ｐｄ－１及び４－１ｂｂの融合タンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023045262A Active JP7746323B2 (ja) | 2016-03-23 | 2023-03-22 | Ｐｄ－１及び４－１ｂｂの融合タンパク質 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US11365237B2 (https=) |
| EP (2) | EP3433269B1 (https=) |
| JP (2) | JP7250519B2 (https=) |
| CN (1) | CN109195985B (https=) |
| AU (1) | AU2017236069B2 (https=) |
| CA (1) | CA3017036A1 (https=) |
| ES (1) | ES2962588T3 (https=) |
| WO (1) | WO2017162797A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3298033T5 (pl) | 2015-05-18 | 2023-10-30 | TCR2 Therapeutics Inc. | Kompozycje i zastosowania medyczne do reprogramowania TCR z zastosowaniem białek fuzyjnych |
| DK3909972T5 (da) | 2015-06-19 | 2024-08-05 | Sebastian Kobold | Pd1-cd28-fusionsproteiner og disses anvendelse i medicin |
| EP3433269B1 (en) * | 2016-03-23 | 2023-09-27 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Fusion proteins of pd-1 and 4-1bb |
| JP7291396B2 (ja) | 2016-11-22 | 2023-06-15 | ティーシーアール２ セラピューティクス インク． | 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法 |
| AU2017382243A1 (en) * | 2016-12-22 | 2019-05-02 | Windmil Therapeutics, Inc. | Compositions and methods for modulating the immune system |
| WO2018181390A1 (ja) * | 2017-03-31 | 2018-10-04 | 東亞合成株式会社 | Ｐｄ－１シグナル配列を有する抗腫瘍ペプチドおよびその利用 |
| EP3820887A4 (en) * | 2018-07-11 | 2022-04-20 | KAHR Medical Ltd. | Pd1-4-1bbl variant fusion protein and methods of use thereof |
| KR102351041B1 (ko) * | 2018-12-19 | 2022-01-13 | 한국화학연구원 | 인간 lrrc24 단백질 유래 세포막 투과 도메인 |
| EP3908664A4 (en) * | 2019-01-07 | 2023-01-25 | Thomas Jefferson University | MULTIFUNCTIONAL FUSION PROTEINS AND THEIR USES |
| AU2020315796A1 (en) * | 2019-07-19 | 2022-02-24 | Memorial Hospital For Cancer And Allied Diseases | Fusion polypeptide for immunotherapy |
| CN115956086A (zh) * | 2020-05-06 | 2023-04-11 | 萨摩亚商柏沛生医股份有限公司 | 用于针对癌症及传染病的免疫疗法的融合蛋白 |
| WO2022036495A1 (en) * | 2020-08-17 | 2022-02-24 | Utc Therapeutics Inc. | Lymphocytes-antigen presenting cells co-stimulators and uses thereof |
| CA3198363A1 (en) * | 2020-10-09 | 2022-04-14 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Methods and compositions comprising pd1 chimeric polypeptides |
| KR102618718B1 (ko) * | 2021-01-11 | 2023-12-29 | 주식회사 유틸렉스 | 항-4-1bb 항체 및 pd-1 단백질 또는 이의 단편을 포함하는 이중특이적 에피토프 결합 단백질 및 이의 용도 |
| WO2023025779A1 (en) * | 2021-08-25 | 2023-03-02 | Medigene Immunotherapies Gmbh | Combination of antigen specific t cell receptors and chimeric co-stimulatory receptors |
| US20260055159A1 (en) * | 2022-08-23 | 2026-02-26 | Medigene Immunotherapies Gmbh | Combination of ny-eso-1 specific t cell receptors and chimeric co-stimulatory receptors |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2014001222A (es) * | 2011-07-29 | 2014-09-15 | Univ Pennsylvania | Receptores coestimuladores de cambio. |
| US9688740B2 (en) * | 2011-10-26 | 2017-06-27 | National Cancer Center | Mutant CTLA4 gene transfected T cell and composition including same for anticancer immunotherapy |
| AU2013204922B2 (en) * | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
| JP6493692B2 (ja) * | 2013-03-15 | 2019-04-10 | セルジーン コーポレイション | 修飾されたｔリンパ球 |
| UY35468A (es) * | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| CN105377897A (zh) | 2013-05-03 | 2016-03-02 | 俄亥俄州创新基金会 | Cs1-特异性嵌合抗原受体工程化的免疫效应细胞 |
| US20170335281A1 (en) * | 2014-03-15 | 2017-11-23 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
| ES2878449T3 (es) * | 2014-07-24 | 2021-11-18 | 2Seventy Bio Inc | Receptores antigénicos quiméricos de BCMA |
| EP4205749A1 (en) * | 2014-07-31 | 2023-07-05 | Novartis AG | Subset-optimized chimeric antigen receptor-containing cells |
| BR112017013981A2 (pt) * | 2015-01-26 | 2018-01-02 | Cellectis | receptores antigênicos quiméricos com uma única cadeia específicos anti-cll1 (sccars) para imunoterapia de câncer |
| US10828353B2 (en) * | 2015-01-31 | 2020-11-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for T cell delivery of therapeutic molecules |
| WO2016138846A1 (en) * | 2015-03-02 | 2016-09-09 | Shanghai Sidansai Biotechnology Co., Ltd | Reducing immune tolerance induced by pd‐l1 |
| EP4406604A3 (en) * | 2015-03-05 | 2024-10-23 | Fred Hutchinson Cancer Center | Immunomodulatory fusion proteins and uses thereof |
| PL3298033T5 (pl) * | 2015-05-18 | 2023-10-30 | TCR2 Therapeutics Inc. | Kompozycje i zastosowania medyczne do reprogramowania TCR z zastosowaniem białek fuzyjnych |
| CN104829733B (zh) * | 2015-05-25 | 2018-06-05 | 广州百暨基因科技有限公司 | 抗原结合单元稳定的嵌合抗原受体及制备方法与应用 |
| DK3909972T5 (da) * | 2015-06-19 | 2024-08-05 | Sebastian Kobold | Pd1-cd28-fusionsproteiner og disses anvendelse i medicin |
| JP2018520679A (ja) * | 2015-06-29 | 2018-08-02 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 免疫チェックポイントキメラ抗原受容体療法 |
| CA2997551A1 (en) * | 2015-09-04 | 2017-03-09 | Memorial Sloan Kettering Cancer Center | Immune cell compositions and methods of use |
| JP2019509738A (ja) * | 2016-03-11 | 2019-04-11 | ブルーバード バイオ， インコーポレイテッド | ゲノム編集された免疫エフェクター細胞 |
| EP3433269B1 (en) * | 2016-03-23 | 2023-09-27 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Fusion proteins of pd-1 and 4-1bb |
| CN111819192A (zh) * | 2018-03-02 | 2020-10-23 | 艾洛基治疗公司 | 可诱导的嵌合细胞激素受体 |
| EP3774906A1 (en) * | 2018-03-28 | 2021-02-17 | Cero Therapeutics, Inc. | Chimeric tim4 receptors and uses thereof |
-
2017
- 2017-03-23 EP EP17713250.3A patent/EP3433269B1/en active Active
- 2017-03-23 EP EP23193951.3A patent/EP4286522A3/en active Pending
- 2017-03-23 JP JP2018549452A patent/JP7250519B2/ja active Active
- 2017-03-23 ES ES17713250T patent/ES2962588T3/es active Active
- 2017-03-23 US US16/087,262 patent/US11365237B2/en active Active
- 2017-03-23 CA CA3017036A patent/CA3017036A1/en active Pending
- 2017-03-23 AU AU2017236069A patent/AU2017236069B2/en active Active
- 2017-03-23 WO PCT/EP2017/056931 patent/WO2017162797A1/en not_active Ceased
- 2017-03-23 CN CN201780031958.9A patent/CN109195985B/zh active Active
-
2022
- 2022-06-08 US US17/835,936 patent/US12516101B2/en active Active
-
2023
- 2023-03-22 JP JP2023045262A patent/JP7746323B2/ja active Active
- 2023-11-16 US US18/510,940 patent/US20240247046A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019512251A5 (https=) | ||
| JP2017537627A5 (https=) | ||
| JP2019500894A5 (https=) | ||
| JP2018518990A5 (https=) | ||
| RU2017111298A (ru) | Т-КЛЕТКИ С КОСТИМУЛИРУЮЩИМ ХИМЕРНЫМ АНТИГЕННЫМ РЕЦЕПТОРОМ, НАЦЕЛЕННЫЕ НА IL13Rα2 | |
| FI3824905T3 (fi) | Menetelmä ja koostumuksia soluimmunoterapiaa varten | |
| RU2018113510A (ru) | Химерные рецепторы антигена, нацеленные на psca | |
| JP2018532407A5 (https=) | ||
| CN112673025B (zh) | 一种包含第三信号受体的嵌合抗原受体及其应用 | |
| ES2962588T3 (es) | Proteínas de fusión de PD-1 y 4-1BB | |
| RU2017121826A (ru) | Т-клетки, модифицированные химерным рецептором антигена, нацеленным на cs1 | |
| CN112154204A (zh) | 基因工程化的细胞及应用 | |
| JP2017537622A5 (https=) | ||
| JP2018029594A5 (https=) | ||
| JP2017538401A5 (https=) | ||
| JP2017535292A5 (https=) | ||
| JP2018508219A5 (https=) | ||
| JP2016534717A5 (https=) | ||
| JP2018029595A5 (https=) | ||
| JP2018501786A5 (https=) | ||
| JP2019509063A5 (https=) | ||
| RU2015142999A (ru) | Слитые белки, содержащие связывающие части pdgf и vegf, и способы их применения | |
| JP2016520074A5 (https=) | ||
| EP4299137A3 (en) | Extracellular vesicle comprising a fusion protein having fc binding capacity | |
| NZ739448A (en) | Transgene genetic tags and methods of use |